Idelalisib-d5

• Description:

  Idelalisib-d5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor[1].

• Product Name Alternative:

  CAL-101 D5; GS-1101 D5

• UNSPSC:

  12352005

• Target:

  Autophagy; PI3K

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy; PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  98.35

• Solubility:

  10 mM in DMSO|DMF : ≥ 30mg/mL|DMSO : ≥ 25mg/mL|Ethanol : ≥ 15mg/mL

• Smiles:

  O=C1N(C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5

• Molecular Formula:

  C22H13D5FN7O

• Molecular Weight:

  420.45

• References & Citations:

  [1]Lannutti BJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 2011, 117 (2), 591-594.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1830330-31-8]